

IN THE CLAIMS

Please amend the claims as shown below. The following claim listing replaces all previously presented claims.

1. (Currently amended) A fusion peptide sequence, ~~composed of~~ comprising:
two peptides from interferons, said peptides being bound together with a linker, said linker consisting of at least ~~of~~ one amino acid residue,
the fusion peptide further containing at least 10 ~~identical~~ amino acid residues selected from in the top-horizontal line ~~in of~~ the following table:

L	T	E	K	K	Y	S	P	S	S	L	K	D	R	H	D	F
	R	R	R	R	H	R	R	A	A		Q	A	K	N	E	
	Q	D	N	D		D	D	T	T		E	Y		M	N	
	M	L	M	N		N	L	G	G		T			K	Y	
	I	S		S			S				M			Q		
	K	K		G			H							A		
	E	A		E			A									
		G		I												

and wherein,

each amino acid residue ~~of in the~~ top-horizontal line sequence can be substituted ~~modified~~
with any ~~of the~~ amino acid residues in vertical line under it in the table.

2. (Currently amended) A drug composition comprising ~~including one or more~~ at least one of ~~peptide~~ one peptide according to Claim 1.

3. (Currently amended) A fusion ~~recombinant~~ protein consisting essentially of ~~involving a~~ carrier protein and at least one or more of ~~peptides~~ peptides according to Claim 1, said peptide being - fused to said ~~recombinant~~ carrier protein.

4. (Currently amended) A drug composition including at least one ~~one or more of~~ ~~recombinant~~ fusion proteins according to Claim 3.

5. (Currently amended) ~~A~~ The fusion protein according to Claim 3, wherein the carrier protein is selected from a group consisting of albebetin, serum albumin, ~~or~~ and immunoglobulin G.

6. (Currently amended) ~~The A-~~ fusion peptide sequence according to Claim 1, wherein the linker has a sequence ~~is of~~ ~~-s~~ Ser ~~-s~~ Ser.

7. (New) The fusion peptide sequence of claim 6, wherein the fusion peptide is according to SEQ ID NO:3.

8. (New) The fusion peptide sequence of claim 1, wherein the linker consists of two short side chain amino acids.

9. (New) The fusion peptide sequence of claim 8, wherein the fusion peptide is according to SEQ ID NO: 4.

10. (New) The fusion peptide according to claim 1, wherein the interferon is human interferon $\alpha 2$.


11. (New) The fusion protein of claim 5, wherein the peptide is according to SEQ ID NO:3 and the carrier protein is albebetin.

12. (New) The fusion protein of claim 5, wherein the peptide is according to SEQ ID NO:4 and the carrier protein is albebetin.

13. (New) The drug composition according to claim 4, wherein the peptide is according to SEQ ID NO:3 and the carrier protein is albebetin.

14. (New) The drug composition according to claim 4, wherein the peptide is according to SEQ ID NO:4 and the carrier protein is albebetin.

Yours truly,



John Dodds/Leea Susanne Somersalo
Attorney of the Applicants
Reg. no. 45533